Brief: Actuate Therapeutics- To Collaborate With Incyte Corporation On Clinical Trials
06/08/2025 13:52
Aug 6 (Reuters) - Actuate Therapeutics Inc ACTU.O: ACTUATE THERAPEUTICS- TO COLLABORATE WITH INCYTE CORPORATION ON CLINICAL TRIAL OF ELRAGLUSIB IN COMBINATION WITH RETIFANLIMAB AND MFOLFIRINOX Source text: ID:nGNX3wJpQm Further company coverage: ACTU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actuate Therapeutics
See all newsActuate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Actuate Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Brief: Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
Brief: Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing